drugset / Trial / NCT01071070

Evaluate Safety and Efficacy of Paricalcitol in Reducing Serum Intact Parathyroid Hormone in Chronic Kidney Disease

NCT01071070

Phase 3 Completed 216 enrolled Abbott
RandomizedSingle-groupSingle-blindTreatment

Summary

Evaluate Safety and Efficacy of Paricalcitol in Reducing Serum Intact Parathyroid Hormone in Chronic Kidney Disease

Timeline

Start
2009-11
Primary completion
2010-11
Completion
2010-11

Drugs

EvaluationDrugModalityDoseRoute
Comparator Paricalcitol Other / unclassified 0.04 ug/kg